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Skeletal muscle carnitine loading increases energy
expenditure, modulates fuel metabolism gene networks
and prevents body fat accumulation in humans
Francis B. Stephens, Benjamin T. Wall, Kanagaraj Marimuthu, Chris E. Shannon,
Dumitru Constantin-Teodosiu, Ian A. Macdonald and Paul L. Greenhaff
MRC/Arthritis Research UK Centre for Musculoskeletal Ageing Research, School of Biomedical Sciences, University of Nottingham, Nottingham, UK
Key points
• Carnitine is a substrate for the carnitine palmitoyltransferase 1 enzyme, a rate-limiting step in
fatty acid oxidation within skeletal muscle.
• Insulin stimulates carnitine transport into skeletal muscle.
• A 20% increase in muscle carnitine content, achieved via 12 weeks of twice daily
supplementation of a beverage containing 1.36 g of L-carnitine and 80 g of carbohydrate (in
order to stimulate insulin-mediated muscle carnitine transport), prevented an 18% increase in
body fat mass associated with carbohydrate supplementation alone in healthy young men.
• A novel finding of the present study was that this prevention of fat gain was associated with
a greater energy expenditure and fat oxidation during low-intensity physical activity, and an
adaptive increase in expression of gene networks involved inmuscle insulin signalling and fatty
acid metabolism.
• Implications to health warrant further investigation, particularly in obese individuals who have
a reduced reliance on muscle fat oxidation during exercise.
Abstract Twelve weeks of daily L-carnitine and carbohydrate feeding in humans increases skeletal
muscle total carnitine content, and prevents body mass accrual associated with carbohydrate
feeding alone. Here we determined the influence of L-carnitine and carbohydrate feeding on
energy metabolism, body fat mass and muscle expression of fuel metabolism genes. Twelve males
exercised at 50%maximal oxygen consumption for 30min once before and once after 12 weeks of
twice daily feeding of 80 g carbohydrate (Control, n= 6) or 1.36 g L-carnitine+ 80 g carbohydrate
(Carnitine, n= 6). Maximal carnitine palmitolytransferase 1 (CPT1) activity remained similar
in both groups over 12 weeks. However, whereas muscle total carnitine, long-chain acyl-CoA
and whole-body energy expenditure did not change over 12 weeks in Control, they increased in
Carnitine by 20%, 200% and 6%, respectively (P< 0.05). Moreover, body mass and whole-body
fat mass (dual-energy X-ray absorptiometry) increased over 12 weeks in Control by 1.9 and
1.8 kg, respectively (P< 0.05), but did not change in Carnitine. Seventy-three of 187 genes
relating to fuel metabolismwere upregulated in Carnitine vs. Control after 12 weeks, with ‘insulin
signalling’, ‘peroxisome proliferator-activated receptor signalling’ and ‘fatty acid metabolism’ as
the three most enriched pathways in gene functional analysis. In conclusion, increasing muscle
total carnitine in healthy humans can modulate muscle metabolism, energy expenditure and
body composition over a prolonged period, which is entirely consistent with a carnitine-mediated
increase in muscle long-chain acyl-group translocation via CPT1. Implications to health warrant
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further investigation, particularly in obese individuals who have a reduced reliance on muscle fat
oxidation during low-intensity exercise.
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Introduction
As a substrate for carnitine palmitoyltransferase 1 (CPT1),
carnitine translocates long-chain acyl groups across the
otherwise impermeable inner mitochondrial membrane
for subsequent β-oxidation (Fritz & Yue, 1963). A series
of studies from our laboratory have suggested that
an insulin-mediated augmentation of skeletal muscle
total carnitine content can increase CPT1 flux and
mitochondrial long-chain acyl group translocation in vivo,
and result in a reciprocal inhibition of carbohydrate
utilisation. By way of example, we demonstrated that a
15% increase in skeletal muscle total carnitine content,
achieved via intravenous L-carnitine infusion during a 6 h
euglycaemic hyperinsulinaemic clamp in healthy human
volunteers at rest, decreased insulin-stimulated muscle
pyruvate dehydrogenase complex (PDC) activation
and muscle lactate accumulation by 30% and 40%,
respectively, comparedwith control (Stephens et al. 2006).
These findings were particularly remarkable as during
hyperinsulinaemic conditions cytosolic malonyl-CoA,
which is a potent inhibitor of CPT1, would likely be
elevated because of increased glycolytic flux (Rasmussen
et al. 2002; Fig. 6). Furthermore, the morning following
the euglycaemic hyperinsulinaemic clamp in the same
study (Stephens et al. 2006), where a controlled diet was
consumed prior to an overnight fast, muscle long-chain
acyl-CoA and glycogen content had increased by 40% and
30%, respectively, suggesting that a carnitine-mediated
increase in long-chain acyl group translocation had
diverted glucose uptake from oxidation towards storage.
More recently we demonstrated that it is possible
to increase muscle total carnitine content via dietary
means by ingesting 1.36 g L-carnitine in combination
with a beverage containing 80 g of carbohydrate (in
order to stimulate insulin-mediated muscle carnitine
accumulation) twice daily over a 24 week period, which
resulted in a 30% increase inmuscle total carnitine content
compared with carbohydrate feeding alone (Wall et al.
2011). This manipulation of the muscle total carnitine
pool resulted in an 80% increase in muscle free carnitine
availability and a 50% reduction in muscle glycogen
utilisation during low-intensity exercise (50% of maximal
oxygen consumption, V˙O2,max). Collectively these findings
suggest that, in contrast to in vitro observations (McGarry
et al. 1983), under conditions of low to moderately
increased glycolytic flux (insulin or exercise mediated),
muscle free carnitine availability is limiting to the CPT1
reaction and, consequently, the rate ofmuscle fat oxidation
in vivo.
One potentially important observation from the study
of Wall et al. (2011) was that increasing muscle
carnitine content by combined L-carnitine (2.7 g day−1)
and carbohydrate (160 g day−1) feeding prevented a 2 kg
increase in body mass that occurred in the control
group (carbohydrate feeding only) after 12 weeks of
dietary supplementation. It is fair to speculate that this
increase in body mass was attributable to an increase in
body fat mass, and that a carnitine-mediated increase in
long-chain fatty acid oxidation obviated this response in
the carnitine-loaded group. In line with this hypothesis,
accelerating CPT1 flux via knock-out of acetyl-CoA
carboxylase 2 (the enzyme responsible for skeletal muscle
malonyl-CoA synthesis) resulted in a sustained increase
in fatty acid oxidation and energy expenditure compared
with wild-type, along with a 27% reduction in fat
mass and a 42% increase in insulin sensitivity in the
face of high-fat feeding in mice (Choi et al. 2007).
Thus, to provide further mechanistic insight, specifically
regarding muscle genomic adaptation in response to
any carnitine-mediated increase in muscle fat oxidation
and altered metabolic flux, we used pathway-focussed,
quantitative,RT-PCR-based low-density arrays tomeasure
changes in mRNA abundance of 187 genes involved
in carnitine and fuel metabolism following 12 weeks of
dietary L-carnitine and carbohydrate supplementation
in young, healthy male volunteers eating an otherwise
ad libitum diet (i.e. in positive energy balance). We
hypothesised that any modulation of energy metabolism
(regional fat mass, skeletal muscle CPT1 activity and
fuel metabolism, and whole-body fatty acid oxidation
and energy expenditure during low-intensity physical
activity) observed with an increase in muscle carnitine
content would be accompanied by an adaptive change in
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the expression levels of gene networks known to encode
proteins regulating muscle fuel utilisation, mitochondrial
function and insulin signalling in muscle.
Methods
Ethical approval
This study formspartof a chronic L-carnitine feeding study
described by Wall et al. (2011). The only data common to
the two papers are resting muscle total carnitine content.
However, due to tissue availability for the analysis of the
present study, only 12 of the original 14 subjects have been
included, and so total carnitine values differ slightly. Thus,
12 healthy, non-vegetarian, male recreational athletes,
reporting to be weight stable for at least 6 months at
the point of screening, volunteered to participate in the
present study, which was approved by the University
of Nottingham Medical School Ethics Committee in
accordancewith theDeclaration ofHelsinki. Before taking
part in the study, all subjects underwent routine medical
screening, completed a general health questionnaire and
performed an incremental exercise test to exhaustion
on a cycle ergometer (Excalibur, Lode, Groningen, The
Netherlands) in order to determine their rate of V˙O2,max
measured using an online gas analysis system (Vmax,
SensorMedics, Anaheim, CA, USA). All gave their written
consent to take part and were aware that they were
free to withdraw from the experiments at any point.
Before the first experimental visit the subjects were
allocated in a randomised, double-blind manner into
two experimental groups as described previously (Wall
et al. 2011); Control (age 25.3± 2.1 years, body mass
index 22.1± 0.9 kgm−2 and V˙O2,max 3.6± 0.3 l min−1)
and Carnitine (age 28.5± 2.1 years, body mass index
24.4± 0.8 kgm−2 and V˙O2,max 4.1± 0.1 l min−1).
Experimental protocol
On two occasions separated by 12 weeks, volunteers
reported to our laboratory following an overnight
fast, and having abstained from strenuous exercise
and alcohol consumption for the previous 48 h. On
arrival at the laboratory subjects were weighed and
had their body composition measured by dual-energy
X-ray absorptiometry (DEXA; Lunar Prodigy, GEMedical
Systems, Bucks, UK). Volunteers then exercised for 30min
on the cycle ergometer at a workload corresponding
to 50% V˙O2,max with oxygen consumption and carbon
dioxide production measurements obtained for 3 min
periods at 7 and 17min. Following the first experimental
visit, subjects were instructed to consume a 700ml
orange-flavoured beverage twice daily for 12 weeks
containing either 80 g of carbohydrate (Vitargo; Swecarb
AB, Stockholm, Sweden; Control) or 80 g of carbohydrate
in combinationwith 2 g of L-carnitine L-tartrate (equating
to 1.36 g of L-carnitine; CarnipureTM, Lonza Group Ltd,
Basel, Switzerland; Carnitine). Volunteers were asked to
ingest the first supplement in the morning and the second
4 h later, in order to maximise the time when plasma
carnitine concentration was elevated in the presence of
increased circulating insulin (Stephens et al. 2007a).
During this 4 h period volunteers could eat ad libitum,
but were requested not to consume nutrition (other than
water) 1 h before or after each supplement.
Sample collection and analysis
A single operator (see Acknowledgements) analysed all
DEXA scans to determine lean soft tissue mass (kg), fat
mass (kg) and bonemineral content (kg) of standard body
regions. The scans were analysed for leg, arm and trunk
composition using the standardised regions specified by
the manufacturer (enCORE 2005 version 9.1; GEMedical
Systems, Bucks, UK). Percentage body fat was calculated
by dividing fat mass by the sum of fat, lean and bonemass.
On each experimental visit, a restingmuscle sample was
obtained from the vastus lateralis using the percutaneous
needle biopsy technique (Bergstro¨m, 1975). Muscle
samples were immediately frozen in liquid nitrogen after
removal from the limb. One portion of each biopsy
sample was freeze dried and stored at −80◦C, whilst the
remainderwas stored ‘wet’ in liquidnitrogen. Freeze-dried
muscle was dissected free of visible blood and connective
tissue, pulverised and used for the determination of free-,
acetyl- and long-chain acyl-carnitine content (Cederblad
et al. 1990). Total carnitine was calculated as the
sum of these carnitine moieties, and has been pre-
sented in part elsewhere (Wall et al. 2011). Long-chain
acyl-CoA content was determined from the same extract
as long-chain acylcarnitine using a modified version
of the radioenzymatic method of Cederblad et al.
(1990), as described previously (Stephens et al. 2006).
Approximately 20mg of wet muscle tissue was used
to determine maximal CPT1 activity using the forward
radioisotope assay (McGarry et al. 1983). Briefly, muscle
was homogenised in 50mM Tris/HCl buffer (pH 7.5)
and immediately used to determine malonyl-CoA
(10μM)-sensitive [14C]palmitoylcarnitine production
from 100μM palmitoyl-CoA, 1 mM L-carnitine and
0.05μCi L-[14C]carnitine, which was normalised to total
protein content using the Bradford assay.
In addition, total RNA was extracted from
approximately 20mg of wet muscle tissue by the
method of Chomczynski & Sacchi (1987) using
Trizol reagent (Invitrogen Ltd, Paisley, UK). Following
spectrophotometric quantification, first-strand cDNAwas
generated from 2μg of RNA using the SuperScript III
cDNA kit (Invitrogen Ltd, Paisley, UK) and stored at
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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−80◦C. Thereafter, the relative mRNA abundance of
187 genes from pathways involved in carnitine, lipid
and carbohydrate metabolism, mitochondrial function
(Krebs’ cycle; oxidative phosphorylation; respiratory
chain), insulin signalling, along with associated nuclear
transcription factors, was determined in duplicate using
custom-designed low-density RT-PCR array microfluidic
cards (192b format; Applied Biosystems, Foster City,
CA, USA) in combination with the ABI PRISM 7900T
sequence detection system and SDS 2.1 software (Applied
Biosystems, Foster City, CA, USA). The candidate genes
were selected from pathway analysis software (Ingenuity
Systems, Redwood City, CA, USA), Pubmed literature
searches and data obtained from our laboratory. A
complete list of details for each gene assay is available
in Supplemental Table 1. The threshold cycle CT was auto-
matically given by the SDS software RQ manager, and
relativemRNA abundancewas calculated using theCT
method, with each subjects’ baseline sample (0 week)
as their own calibrator and α-actin as the endogenous
control. CT values for α-actin did not change across time
points (data not shown).
Calculations and statistical analysis
Indirect calorimetry calculations were performed
according to the non-protein stoichiometric equations
given by Frayn (1983). Total energy expenditure during
exercise was calculated as the sum of energy production
from fat and carbohydrate, assuming that the oxidation
of 1 g of triacylglycerol (862 gmol−1) liberates 39.4 kJ
and 1 g of glucose (180 gmol−1) liberates 15.6 kJ, and
was normalised to lean body mass (DEXA). A two-way
ANOVA (time and treatment factors; Prism 5, Graphpad
Software, La Jolla, CA, USA) was performed to detect
differences within and between treatment groups for
all measures described with the exception of mRNA
abundance (see below). When a significant interaction
effect was observed, a Student’s t test with Bonferroni
correction was performed to locate differences. Statistical
significance was declared at P< 0.05. Due to the relatively
large number of genes measured, significance analysis of
microarray was performed between the relative mRNA
abundance values forControl andCarnitine on a two-class
unpaired basis with 924 permutations and false discovery
rates (FDRs) of <5% and <1% (MeV 4.5, TM4; Saeed
et al. 2006). Hierarchical cluster analysis using Pearson’s
correlation was subsequently performed on the genes
with a significant differential expression (MeV 4.5, TM4),
as well as gene enrichment analysis against the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway
(DAVID 6.7, NIH; Huang et al. 2009). The original gene
list, as opposed to the whole human genome, was used as a
background for the enrichment analysis of the significant
genes in order to eliminate any bias from the selection of
the genes on the original list. All the values presented in
the text, tables and figures represent mean± SEM.
Results
Muscle total carnitine content
Resting skeletal muscle total carnitine content at base-
line (0 week) was similar in Control and Carnitine
(Fig. 1). However, whereas 12 weeks of carbohydrate
supplementation had no effect on the muscle total
carnitine pool in Control, daily L-carnitine and
carbohydrate supplementation for 12 weeks increased
muscle total carnitine content in every subject, with a
mean increase of 21% (P< 0.01), such that the change
in total carnitine from baseline was different to Control
(4.5± 0.9 vs. −1.5± 2.3 mmol kg−1 dm in Carnitine and
Control, respectively; P< 0.05).
Body composition
Total body mass calculated by DEXA was the same
as that measured by weighing, and increased in
every subject in Control over 12 weeks (75.1± 4.2 to
77.0± 4.1 kg, respectively; P< 0.05), but did not change
Figure 1. Skeletal muscle total carnitine
Resting skeletal muscle total carnitine content before (0) and
12 weeks after twice daily oral ingestion of either 80 g of
carbohydrate (Control; open bars; n = 6) or 80 g of carbohydrate
containing 1.36 g L-carnitine (Carnitine; filled bars; n = 6). All values
are means ± SEM. ∗∗P < 0.01, significantly greater than week 0;
†P < 0.05, significantly greater than Control at 12 weeks.
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in Carnitine (76.6± 2.3 and 76.7± 2.2 kg, respectively).
The 1.9± 0.7 kg increase in body mass over 12 weeks
in Control was entirely accounted for by an increase of
1.8± 0.7 kg inbody fatmass (P< 0.05; Fig. 2), 1.0± 0.4 kg
of which was due to increased trunk fat mass (P< 0.05;
Fig. 2) and 0.7± 0.2 kg was due to increased leg fat mass
(P< 0.05; Fig. 2). Whole body, trunk and leg fat mass
increased in every subject in Control. Lean body mass
did not change in Control (60.3± 2.8 and 60.1± 2.6 kg,
respectively) or Carnitine over 12 weeks (61.5± 1.2 and
61.9± 1.4 kg, respectively).
Low-intensity exercise
The volunteers cycled at similar absolute workloads of
115± 13W and 137± 12W in Control and Carnitine,
respectively, at 0 and 12 weeks. Whereas energy
expenditure during exercise inControl remained relatively
constant over 12 weeks (Fig. 3A), energy expenditure
increased by 6% in Carnitine after 12 weeks (P< 0.05;
Fig. 3A). The change in energy expenditure from
baseline was positive in every subject in Carnitine
and markedly different to Control (36.0± 12.0 vs.
−26.9± 12.6 J min−1 kg−1 lean mass in Carnitine and
Control, respectively; P< 0.01; Fig. 3A), and likely due to
the differences in fat oxidation as carbohydrate oxidation
during exercise did not change from baseline after
Figure 2. Body composition
Trunk (filled bars), leg (hatched bars) and arm (open bars) fat mass
before (0) and 12 weeks after twice daily oral ingestion of either 80 g
of carbohydrate (Control; n = 6) or 80 g of carbohydrate containing
1.36 g L-carnitine (Carnitine; n = 6). All values are means ± SEM.
∗P < 0.05, total body fat mass significantly greater than week 0;
‡P < 0.05, leg and trunk fat mass significantly greater than week 0.
12 weeks of supplementation in Control (22.0± 1.6 vs.
25.8± 2.4 mg min−1 kg−1 lean mass, respectively) or
Carnitine (27.3± 1.5 vs. 28.1± 1.7 mg min−1 kg−1 lean
mass). For example, there was an interaction effect for fat
oxidation (P< 0.05) and, although fat oxidation during
exercise did not differ significantly from baseline after
12 weeks in Control (P= 0.13; Fig. 3B), there was a
Figure 3. Exercise indirect calorimetry
Whole-body energy expenditure (A) and fat oxidation (B) during
20 min of cycling exercise at 50% V˙O2,max before (0) and 12 weeks
after twice daily oral ingestion of either 80 g of carbohydrate
(Control; open bars; n = 6) or 80 g of carbohydrate containing
1.36 g L-carnitine (Carnitine; filled bars; n = 6). All values are
means ± SEM. ∗P < 0.05, significantly greater than 0; ††P < 0.01,
change over 12 weeks significantly greater than Control.
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trend for it to increase by 10% in Carnitine (P= 0.09;
Fig. 3B), such that the change in the rate of fat oxidation
from baseline was markedly different between Carnitine
and Control (0.6± 0.3 vs. −2.1± 1.2 mgmin−1 kg−1 lean
mass, respectively; P< 0.05). Furthermore, the increase
in energy expenditure over 12 weeks in Carnitine, with
no change in carbohydrate oxidation, reflects the fact that
there was only a trend for an interaction effect for the
respiratory exchange ratio data over 12 weeks (0.86± 0.01
to 0.89± 0.01 and 0.89± 0.01 to 0.88± 0.01 in Control
and Carnitine, respectively; P= 0.08).
Muscle CPT1 activity and long-chain acyl-CoA content
There were no differences in skeletal muscle maximal
CPT1 activity before or after 12 weeks in Control or
Carnitine (Fig. 4A). Skeletal muscle total long-chain
acyl-CoA content under resting fasted conditions did not
change after 12 weeks in Control, but increased from a
similar baseline concentration by approximately fourfold
after 12 weeks in Carnitine (P< 0.05), such that it was also
fourfold greater than Control at this corresponding time
point (P< 0.05; Fig. 4B).
Gene expression
Seventy-three genes were differentially expressed (<5%
FDR) between Control and Carnitine over 12 weeks, with
the fold change from 0 to 12 weeks for all genes being
greater in Carnitine compared with Control (mean fold
change 0.92± 0.01 vs. 1.33± 0.02, respectively; Table 1)
as a result of predominantly decreased expression in
Control and increased expression in Carnitine. The
individual responses for each subjects’ fold change
from baseline (0 week) for the 73 genes are shown on
the heatmap in Fig. 5, which also depicts the gene
cluster following hierarchical analysis. Gene functional
analysis highlighted ‘insulin signalling pathway’ (ACACA,
ACACB,CBL,CRK,GSK3B,GYS1,HK2,MAPK3,PPP1G,
PTPN1, PYGM, RAPGEF1; P= 9.3× 10−12), ‘peroxisome
proliferator-activated receptor (PPAR) signallingpathway’
(ACSL3, CPT1B, CPT2, EHHADH, FABP3, LPL, NR1H3,
PPARA, SLC27A1; P= 2.9× 10−10) and ‘fatty acid
metabolism’ (ACAT1, ACSL3, ALDH3A2, CPT1B, CPT2,
EHHADH, HADHA, HADHB; P= 7.8× 10−10) as the
top three enriched pathways from the KEGG (Fig. 6).
Adjusting the FDR to <1% in order to provide further
insight as to the geneswith themost significant differential
expression between Control and Carnitine revealed six
transcripts (ACAT, PNPLA2, TFAM, PDK2, FOXO3,
CPT1B; highlighted in Table 1 and Fig. 6).
Discussion
The general aim of the present study was to investigate
whether increasing muscle carnitine content over a
12 week period during which L-carnitine was consumed
in combination with a high carbohydrate beverage could
result in the modulation of human energy metabolism.
With this inmind, amajor finding was that a 20% increase
in muscle carnitine content prevented the 1.8 kg increase
in body fat mass associated with daily ingestion of a
high carbohydrate beverage. Moreover, this maintenance
Figure 4. Resting skeletal muscle metabolism
Resting skeletal muscle carnitine palmitoyltransferase 1 (CPT1)
maximal activity (A; n = 5) and long-chain acyl-CoA content (B;
n = 6) before (0) and 12 weeks after twice daily oral ingestion of
either 80 g of carbohydrate (Control; open bars) or 80 g of
carbohydrate containing 1.36 g L-carnitine (Carnitine; filled bars). All
values are means ± SEM. ∗P < 0.05, significantly greater than week
0; †P < 0.05, significantly different from corresponding Control at
12 weeks.
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Table 1. Expression of differentially expressed skeletal muscle
transcripts encoding proteins involved in carnitine and fuel
metabolism pathways after 12 weeks of twice daily oral
ingestion of either 80 g of carbohydrate (Control) or 80 g of
carbohydrate containing 1.36 g L-carnitine (Carnitine)
Pathway Gene ID Control Carnitine
Carnitine synthesis SHMT1 0.97 ± 0.07 1.29 ± 0.08
and transport SLC22A5 0.88 ± 0.08 1.36 ± 0.17
Fat metabolism ACAA1 0.91 ± 0.03 1.27 ± 0.17
ACACA 0.95 ± 0.11 1.54 ± 0.35
ACACB 0.79 ± 0.12 1.14 ± 0.14
ACADL 1.10 ± 0.06 1.36 ± 0.16
ACAT1 1.00 ± 0.02 1.27 ± 0.05
ALDH3A2 0.98 ± 0.08 1.49 ± 0.24
CD36 0.94 ± 0.11 1.22 ± 0.25
CPT1B 0.65 ± 0.05 1.32 ± 0.20
CPT2 0.81 ± 0.08 1.24 ± 0.14
DGAT1 0.94 ± 0.07 1.28 ± 0.09
EHHADH 0.78 ± 0.11 1.62 ± 0.42
FABP3 0.80 ± 0.12 1.25 ± 0.25
HADHA 0.91 ± 0.07 1.27 ± 0.11
HADHB 1.03 ± 0.09 1.47 ± 0.16
LPIN1 0.81 ± 0.13 1.08 ± 0.12
LPL 0.89 ± 0.08 1.93 ± 0.59
PNPLA2 0.78 ± 0.07 1.59 ± 0.17
SLC25A20 0.80 ± 0.10 1.23 ± 0.16
SLC27A1 0.76 ± 0.12 1.09 ± 0.12
UCP3 0.92 ± 0.12 1.39 ± 0.38
Carbohydrate GSK3B 0.92 ± 0.07 1.22 ± 0.08
metabolism GYS1 0.87 ± 0.08 1.13 ± 0.05
HK2 0.85 ± 0.19 1.64 ± 0.51
LDHB 1.08 ± 0.14 1.86 ± 0.46
PDK1 1.03 ± 0.10 1.33 ± 0.11
PDK2 0.76 ± 0.08 1.11 ± 0.05
PDK4 0.80 ± 0.18 1.67 ± 0.59
PYGM 0.92 ± 0.09 1.22 ± 0.18
SLC16A1 0.86 ± 0.06 1.24 ± 0.15
SLC25A10 0.79 ± 0.10 1.51 ± 0.50
TALDO1 1.01 ± 0.06 1.39 ± 0.29
Krebs cycle, oxidative ACO2 0.81 ± 0.05 1.11 ± 0.07
phosphorylation ATP5B 1.00 ± 0.09 1.25 ± 0.12
and respiratory ATP5J2 1.12 ± 0.15 1.56 ± 0.33
chain CKM 0.94 ± 0.07 1.16 ± 0.09
DLST 0.99 ± 0.15 1.38 ± 0.20
IDH2 0.89 ± 0.07 1.13 ± 0.11
NDUFS1 1.03 ± 0.05 1.30 ± 0.15
OGDH 0.91 ± 0.10 1.32 ± 0.12
PC 0.90 ± 0.16 1.59 ± 0.44
SDHA 0.99 ± 0.08 1.30 ± 0.11
SUCLG1 0.95 ± 0.06 1.16 ± 0.09
SURF1 1.08 ± 0.11 1.34 ± 0.09
Insulin signalling and CBL 0.81 ± 0.12 1.52 ± 0.46
associated proteins CRK 0.92 ± 0.09 1.35 ± 0.12
MAPK3 0.98 ± 0.14 1.30 ± 0.13
PDPK1 1.02 ± 0.09 1.30 ± 0.05
PPP1CC 1.04 ± 0.09 1.30 ± 0.06
Table 1. Continued
Pathway Gene ID Control Carnitine
PRKCA 0.83 ± 0.08 1.13 ± 0.10
PRKCQ 0.97 ± 0.08 1.28 ± 0.08
PTEN 0.82 ± 0.11 1.18 ± 0.17
PTPN1 0.84 ± 0.12 1.08 ± 0.08
RAPGEF1 0.84 ± 0.12 1.19 ± 0.06
STX4 0.99 ± 0.11 1.34 ± 0.22
Associated ATF2 1.06 ± 0.08 1.31 ± 0.14
transcription factors DDIT3 1.03 ± 0.13 1.38 ± 0.24
EP300 0.98 ± 0.11 1.24 ± 0.08
ESR1 1.01 ± 0.12 1.24 ± 0.07
FOXJ3 0.94 ± 0.12 1.18 ± 0.10
FOXO3 0.88 ± 0.09 1.30 ± 0.07
MLXIPL 0.95 ± 0.17 1.33 ± 0.17
MYBBP1A 0.80 ± 0.10 1.06 ± 0.05
NCOA1 1.08 ± 0.10 1.33 ± 0.12
NFKB1 1.13 ± 0.11 1.45 ± 0.21
NR1H2 0.88 ± 0.03 1.12 ± 0.11
NR1H3 1.26 ± 0.16 2.30 ± 0.96
PPARA 0.87 ± 0.13 1.31 ± 0.12
RELA 0.93 ± 0.11 1.28 ± 0.14
SREBF2 0.85 ± 0.13 1.17 ± 0.07
STAT3 0.95 ± 0.11 1.32 ± 0.10
TFAM 0.94 ± 0.06 1.34 ± 0.08
All values (n = 6) are means ± SEM and are expressed as relative
mRNA abundance compared with baseline (week 0). All values
significantly greater in Carnitine vs. Control (<5% FDR). Trans-
cripts in bold are significantly greater in Carnitine vs. Control
(<1% FDR).
of body mass was associated with a greater whole-body
energy expenditure during low-intensity physical activity,
accounted for by an increase in fat oxidation, and amarked
adaptive increase in the expression of gene networks
involved in insulin signalling, PPAR signalling and fatty
acid metabolism over and above the decline observed
in Control. Taken together the present findings suggest
that increasing skeletal muscle carnitine content pre-
vented the increased adiposity observed with prolonged
supplementation of a high carbohydrate beverage by
maintaining the capacity to oxidise fat, which is
entirely consistent with a carnitine-mediated increase in
long-chain acyl-group translocation via CPT1.
Twelve weeks of twice daily supplementation with
a beverage containing 80 g of carbohydrate in Control
resulted in a 1.8 kg increase in body mass, which was
almost entirely attributable to an increase in trunk and
leg fat. Assuming adipose tissue contains 30MJ kg−1 this
equates to a positive energy balance of approximately
640 kJ day−1 and suggests that the volunteers in the
Control group were ‘overfed’ carbohydrate (equivalent
to about 40 g day−1). We propose, therefore, that the
increase in muscle carnitine content obviated the effect
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Figure 5. Skeletal muscle gene expression
Heatmap of skeletal muscle transcripts involved in fuel metabolism
pathways after 12 weeks of twice daily oral ingestion of either 80 g
of carbohydrate (Control) or 80 g of carbohydrate containing 1.36 g
L-carnitine (Carnitine). All values are expressed as relative mRNA
abundance compared with baseline (week 0) from individual
subjects (1–6) in each group.
of a long-term increase in daily energy intake from,
predominantly, carbohydrate. Specifically, whilst chronic
daily carbohydrate overfeeding had no effect on energy
expenditure during low-intensity exercise in Control,
which is in agreement with previous reports (Welle et al.
1986; Dirlewanger et al. 2000), energy expenditure during
exercise increased by 0.04 kJ min−1 kg−1 lean mass over
12 weeks in Carnitine such that it was 0.06 kJ min−1 kg−1
lean mass greater than Control. Thus, for the Carnitine
group (60 kg lean mass) to maintain whole-body fat mass
and balance the 640 kJ day−1 increase in energy intake
from carbohydrate overfeeding observed in Control, both
groups would have had to perform just under 3 h of
physical activity at an equivalent of 50% V˙O2,max per
day, which was certainly feasible for the recreational
athletes of the present study. Of course it is possible that
L-carnitine supplementation may have reduced energy
intake in the present study, but we are unaware of any
studies that have reportedweight loss following L-carnitine
supplementation without carbohydrate (Stephens et al.
2007b).
The mechanism underlying the increase in energy
expenditure is not entirely clear, but it is most likely
due to the greater change in the rate of fat oxidation
observed after 12 weeks in Carnitine compared with
Control, in the absence of a change in the rate
of carbohydrate oxidation. As the absolute workload
during exercise did not change in the present study,
and therefore presumably the ATP demand of muscle
contraction, it would suggest that mitochondrial ATP
synthesis was less efficient with greater fat utilisation.
Indeed, unlike glycolysis, the catabolism of fatty acids to
acetyl-CoA also produces FADH as an electron donor,
which has a lower P/O ratio than NADH, and a
well-characterised adaptation to excess fatty acidoxidation
is an increase in mitochondrial uncoupling. Furthermore,
an increased rate of fat oxidation during low-intensity
exercise (50% V˙O2,max) has been linked with increased
energy expenditure and reduced mitochondrial efficiency
during state 3 respiration (i.e. oxygen consumption for a
given amount of ADP; Fernstro¨m et al. 2007), and more
efficient mitochondrial ATP production and increased
P/O ratio during exercise has been associated with
increased carbohydrate oxidation during low-intensity
exercise (50% V˙O2,max; Larsen et al. 2011). Muscle free
carnitine content was not measured after 20min of
exercise in the present study, but in our previous study
a 20% increase in skeletal muscle total carnitine content
following 24 weeks of daily L-carnitine and carbohydrate
feeding resulted in a striking 80% greater availability of
muscle free carnitine following 30min of low-intensity
exercise compared with Control, which was associated
with a 30% reduction in PDC activation and a 55%
reduction inmuscle glycogen utilisation (Wall et al. 2011).
The present study confirms that these previous findings
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were likely due to a relative increase in the rate of fatty acid
oxidationduring exercisewith a dietary-mediated increase
in the muscle total carnitine store, and provides further
support to the suggestion that free carnitine availability is
limiting to the CPT1 reaction in vivo (van Loon et al. 2001;
Roepstorff et al. 2005; Stephens et al. 2007b). Whether
energy expenditure and fat oxidation were also increased
at rest in the Carnitine group in the present study requires
further investigation, but this seems highly likely given
there was a fourfold increase in resting muscle long-chain
acyl-CoA content (which we have previously shown to be
consistent with an increase in muscle carnitine content
and a switch in fuel metabolism at rest; Stephens et al.
2006).
To provide mechanistic insight of the inter-
action between chronically altered metabolic flux
and muscle gene expression (independent of changes
in mitochondrial content; Wall et al. 2011), we
used a pathway-focussed, quantitative, RT-PCR-based
low-density array to determine coordinated expression
of genes involved in the regulation of muscle fuel
metabolism. The relative mRNA abundance of 73 of
the 187 genes measured was increased in the Carnitine
group compared with Control after 12 weeks, with gene
functional analysis highlighting ‘insulin signalling’, ‘PPAR
signalling’ and ‘fatty acid metabolism’ as the three most
enriched functional pathways. The finding that gene
networks within the insulin signalling pathway were
upregulated with a prevention of adiposity, particularly in
the leg region, is perhaps not surprising given the known
association of fatty acid availability, intramyocellular lipid
(IMCL) content and insulin signalling (Savage et al. 2007).
Indeed, the transcript for adipose triglyceride lipase (ATGL
or PNPLA2), a key controlling enzyme in IMCLhydrolysis
(Watt & Steinberg, 2008), was highlighted as significantly
greater in Carnitine compared with Control (<1%
FDR), was downregulated in every Control volunteer,
and clustered tightly with the transcript for carnitine
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Figure 6. Skeletal muscle carnitine loading increases fat metabolism
Schematic diagram illustrating the proposed increase in resting skeletal muscle fat metabolism (red arrows),
gene networks (shaded areas) and expression of highly significant genes (FDR < 1%; highlighted in yellow)
following 12 weeks of carnitine and carbohydrate supplementation (Carnitine) compared with carbohydrate
supplementation alone (Control). [1] An increase in skeletal muscle carnitine content increases carnitine
palmitoyltransferase 1 (CPT1) and fatty acid flux within skeletal muscle, reflected by an increase in long-chain
acyl-CoA content. This suggestion is supported by an increase in ‘PPAR signalling’ and ‘fatty acid metabolism’ gene
networks (red shaded area), and increases in gene expression of PNPLA2 and CPT1B, which encode rate-limiting
steps in intramyocellular lipid (IMCL) hydrolysis and fatty acid oxidation, respectively. [2] We have previously
demonstrated that the resulting carnitine-mediated increase in fatty acid flux and β-oxidation acutely inhibits
carbohydrate oxidation at the level of the pyruvate dehydrogenase (PDH) complex (Stephens et al. 2006). The
present study suggests that chronic regulation at the level of PDH with prolonged elevation of muscle carnitine
content likely occurs via increased fatty acid flux increasing PDK2 gene expression directly, or via increased forkhead
box class O transcription factor (FOXO3) gene expression. [3] Whether increased fatty acid flux and a IMCL hydro-
lysis resulted in reduced fatty acid metabolite accumulation and improved insulin sensitivity [4] in the face of
overfeeding in the present study requires further investigation, particularly as the ‘insulin signalling pathway’ was
the most significantly upregulated gene network (blue shaded area).
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acylcarnitine translocase (SLC25A20), suggesting that a
carnitine-mediated alteration in IMCL metabolism may
have negated the negative effects of carbohydrate over-
feeding on insulin signalling genes (Fig. 6).
The upregulation of ‘PPAR signalling’ and ‘fatty acid
metabolism’ pathways clearly support the suggestion
that the prolonged modulation of energy metabolism
associated with an increase in muscle total carnitine was
due to an increase in fatty acid flux. Indeed, five of the six
transcripts in the <1% FDR gene-set that were greater
in Carnitine compared with Control encode proteins
regulating key steps in IMCL hydrolysis (ATGL), fatty acid
entry into mitochondria (CPT1), terminal β-oxidation
(acetyl-CoA acetyltransferase 1; ACAT1), inhibition of
carbohydrate oxidation (pyruvate dehydrogenase kinase
2; PDK2) and transcriptional control of PDK expression
(forkhead box class O transcription factor 3a; FOXO3;
Kwon et al. 2004). This finding is particularly remarkable
as high carbohydrate ingestion has been shown to blunt
increases in fat oxidative genes in response to stimuli
that promote a switch to fat use (Civitarese et al.
2005). Common to the ‘PPAR signalling’ and ‘fatty acid
metabolism’ functional pathways are genes regulated by
PPARα, a nuclear receptor protein involved in lipid
sensing and the modulation of the expression of key genes
involved in fatty acid metabolism (Feige et al. 2006).
Both saturated and unsaturated long-chain acyl-CoAs
have been demonstrated to be very high-affinity ligands
for PPARα (Hostetler et al. 2005), and accumulation of
intracellular fatty acyl-metabolites has been suggested
to activate PPARα in vivo (Gulick et al. 1994), which
is consistent with fourfold greater long-chain acyl-CoA
content after 12 weeks in Carnitine of the present study.
PPARα is also the main transcriptional regulator of CPT1
in skeletal muscle, the mRNA expression of which was
twofold greater in Carnitine than Control at 12 weeks and
also downregulated in every Control volunteer. Thus, we
propose that increasing muscle total carnitine resulted in
an increase in muscle CPT1 flux and long-chain acyl-CoA
content, which in turn signalled amolecular adaptation to
maintain greater fat oxidation. The finding that maximal
activity of CPT1 did not change over 12 weeks in the pre-
sent study does not support this suggestion (assuming
that maximal CPT1 activity reflects the total amount of
CPT1 protein; Bruce et al. 2009) and so further research
is required. Perhaps CPT1 flux is more important than
content in determining fat oxidation rates, transcriptional
regulation of CPT1 by acyl-groups and PPARα may not
be the only controller of CPT1 protein content (Balda´n
et al. 2004), or the in vitro assay is not a true reflection
of in vivo conditions (Smith et al. 2012). Nevertheless,
consistent with the overall premise of the present study,
PPARα activation in a hamster model of obesity increased
mitochondrial β-oxidation 1.6-fold in skeletal muscle
without affecting glucose utilisation, resulting in increased
energy expenditure and 17% body mass loss (Minnich
et al. 2001).
In conclusion, this is the first study to demonstrate
that increasing skeletal muscle carnitine content in
healthy humans can modulate energy metabolism over
a prolonged period, as reflected by a prevention of
an increase in adiposity in abdominal and leg regions,
an increase in energy expenditure during low-intensity
exercise, and a robust increase in the expression of
metabolic genes regulating muscle fuel selection in
response to 12 weeks of carbohydrate overfeeding. In
line with the role of carnitine in the translocation
of long-chain acyl-groups via CPT1, these important
findings are most likely due to an increase in the rate
of fat oxidation compared with Control at rest and
during low-intensity exercise. This is consistent with
animal models of increased CPT1 flux, in which a
sustained increase in fatty acid oxidation and energy
expenditure occur along with reduced fat mass and
improved insulin sensitivity (Minnich et al. 2001; Choi
et al. 2007; Bruce et al. 2009; Glund et al. 2012). These
findingshave clearhealth implications andwarrant further
investigation, particularly in obese individuals who have
a reduced reliance on IMCL oxidation at rest and during
low-intensity exercise (van Loon, 2004; Perreault et al.
2010), as well as abdominal adipose tissue accumulation,
which predisposes to the development of insulin resistance
and type 2 diabetes. Future research should attempt to
control habitual physical activity levels, energy intake
and energy expenditure during larger scale L-carnitine
supplementation studies in order tomore clearly elucidate
how increasing skeletal muscle carnitine content prevents
fat mass gain during overfeeding, and the potential for
similar L-carnitine supplementation regimes to improve
body fat loss during energy restriction.
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